Eagle Pharmaceuticals Inc

Company Profile

Eagle Pharmaceuticals Inc had its IPO on 2014-02-12 under the ticker symbol EGRX.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Eagle Pharmaceuticals Inc has a staff strength of 134 employees.

Stock update

Shares of Eagle Pharmaceuticals Inc opened at $15.74 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $15.74 - $16.36, and closed at $16.29.

This is a +2.91% increase from the previous day's closing price.

A total volume of 99,105 shares were traded at the close of the day’s session.

In the last one week, shares of Eagle Pharmaceuticals Inc have slipped by -8.53%.

Eagle Pharmaceuticals Inc's Key Ratios

Eagle Pharmaceuticals Inc has a market cap of $242.71 million, indicating a price to book ratio of 1.724 and a price to sales ratio of 1.2927.

In the last 12-months Eagle Pharmaceuticals Inc’s revenue was $267.04 million with a gross profit of $221.67 million and an EBITDA of $69.08 million. The EBITDA ratio measures Eagle Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Eagle Pharmaceuticals Inc’s operating margin was 19.62% while its return on assets stood at 8.92% with a return of equity of -1.16%.

In Q1, Eagle Pharmaceuticals Inc’s quarterly earnings growth was a negative -87.1% while revenue growth was a negative 42.8%.

Eagle Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

11.3379

Trailing PE

0

PEG

0.91

Its diluted EPS in the last 12-months stands at $-0.28 per share while it has a forward price to earnings multiple of 11.3379 and a PEG multiple of 0.91. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eagle Pharmaceuticals Inc’s profitability.

Eagle Pharmaceuticals Inc stock is trading at a EV to sales ratio of 1.5055 and a EV to EBITDA ratio of 7.5687. Its price to sales ratio in the trailing 12-months stood at 1.2927.

Eagle Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$414.18 million

Total Liabilities

$97.81 million

Operating Cash Flow

$-12558000.00

Capital Expenditure

$58000

Dividend Payout Ratio

0%

Eagle Pharmaceuticals Inc ended 2023 with $414.18 million in total assets and $0 in total liabilities. Its intangible assets were valued at $414.18 million while shareholder equity stood at $242.85 million.

Eagle Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $97.81 million in other current liabilities, 18000.00 in common stock, $117.25 million in retained earnings and $45.03 million in goodwill. Its cash balance stood at $21.90 million and cash and short-term investments were $21.90 million. The company’s total short-term debt was $7,500,000 while long-term debt stood at $68.83 million.

Eagle Pharmaceuticals Inc’s total current assets stands at $192.49 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $114.95 million compared to accounts payable of $17.11 million and inventory worth $44.14 million.

In 2023, Eagle Pharmaceuticals Inc's operating cash flow was $-12558000.00 while its capital expenditure stood at $58000.

Comparatively, Eagle Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$16.29

52-Week High

$47.71

52-Week Low

$18.03

Analyst Target Price

$29.5

Eagle Pharmaceuticals Inc stock is currently trading at $16.29 per share. It touched a 52-week high of $47.71 and a 52-week low of $47.71. Analysts tracking the stock have a 12-month average target price of $29.5.

Its 50-day moving average was $18.53 and 200-day moving average was $25.33 The short ratio stood at 6.35 indicating a short percent outstanding of 0%.

Around 1309.9% of the company’s stock are held by insiders while 8956.8% are held by institutions.